Efficacy and Safety of Oral Conivaptan: A V<sub>1A</sub>/V<sub>2</sub>Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-Controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia

2006192 citationsJournal Articlebronze Open Access

Authors

Oral conivaptan (40 and 80 mg/d) was well tolerated and efficacious in correcting serum [Na(+)] in hyponatremia.

Good health and well-being

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 91, Issue 6, pp. 2145-2152

Field-Weighted Citation Impact: 15.59